Michael Spartalis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Michael Spartalis has a total of 343 co-authors. Here are the top co-authors by number of shared publications:
Eleftherios Spartalis
Laboratory of Experimental Surgery and Surgical Research ‘N. S. Christeas’, Medical School, National and Kapodistrian University of Athens, Athens, Greece
57 shared publicationsAntonios Athanasiou
St James Univ Hosp, Leeds Teaching Hosp NHS Trust, Dept Surg, Leeds, W Yorkshire, England
22 shared publications- Eleftherios Spartalis
Laboratory of Experimental Surgery and Surgical Research, University of Athens, Medical School, Athens, Greece
20 shared publications Eleni Tzatzaki
Division of Cardiology, Onassis Cardiac Surgery Center, Athens, Greece
19 shared publicationsVassilis Voudris
Division of Cardiology, Onassis Cardiac Surgery Center, Athens, Greece
19 shared publications- Demetrios Moris
MedStar Georgetown Transplant Institute, MedStar Georgetown University Hospital, 3800 Reservoir Road NW, Washington, DC 20007, USA
18 shared publications
Latest Publications
- Open Access
- 2 March 2026
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2026 (3) , CD016334
Artificial intelligence-enabled electrocardiography to predict impending episodes of ventricular tachycardia in individuals under continuous heart rhythm monitoring
This is a protocol for a Cochrane Review (prognosis). The objectives are as follows: To identify and evaluate AI-based prognostic models, in development and external validation studies, which predict impending episodes of ventricular tachycardia from continuous surface electrocardiogram (ECG) recordings in individuals at elevated risk for ventricular arrhythmias due to any relevant underlying condition.
- 2 March 2026
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2026 (3) , CD016334
Open AccessArtificial intelligence-enabled electrocardiography to predict impending episodes of ventricular tachycardia in individuals under continuous heart rhythm monitoring
This is a protocol for a Cochrane Review (prognosis). The objectives are as follows: To identify and evaluate AI-based prognostic models, in development and external validation studies, which predict impending episodes of ventricular tachycardia from continuous surface electrocardiogram (ECG) recordings in individuals at elevated risk for ventricular arrhythmias due to any relevant underlying condition.
- Top Cited Papers
- 18 July 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (1) , 94-106
Major arrhythmias in non-dilated left ventricular cardiomyopathy: a novel prediction score
Background and Aims: The prediction of the first major arrhythmic event (MAE) is still an unmet need in the recently defined scenario of non-dilated left ventricular cardiomyopathy (NDLVC). Methods: A cohort of 337 patients with NDLVC and no history of MAE was retrospectively identified at two large centres. Patient-tailored diagnostic workup included cardiac magnetic resonance (CMR), endomyocardial biopsy, and genetic testing. The primary endpoint was the occurrence of the first MAE, including sustained ventricular tachycardia (VT), ventricular fibrillation, or appropriate implantable cardioverter-defibrillator therapy, by 60-month follow-up. A pool of 216 NDLVC patients from 11 European centres served as a validation cohort. Results: In the study cohort (mean age 37 ± 15 years, 62% male), the mean left ventricular ejection fraction (LVEF) was 52 ± 8%, and 79% of patients had late gadolinium enhancement (LGE) at baseline CMR. By 60-month follow-up, 51 patients (15%) experienced a MAE. The primary endpoint was predicted by male sex [hazard ratio (HR) 2.4, 95% confidence interval (CI) 1.3–4.4, P = .007], baseline non-sustained VT (HR 3.1, 95% CI 1.7–5.6, P < .001), LVEF < 45% (HR 5.5, 95% CI 2.7–11.0, P < .001), septal (HR 2.0, 95% CI 1.0–4.0, P = .046) and ring-like pattern of LGE (HR 1.3, 95% CI .6–2.6, P = .54), pathogenic/likely pathogenic variants in guideline-defined high-risk genes (HR 4.6, 95% CI 2.3–9.1, P < .001), and biopsy/CMR-proven myocardial inflammation (HR 15.7, 95% CI 6.1–40.3, P < .001). The results were confirmed in the validation cohort (Uno’s C-index 0.81, 95% CI .75–.88). A novel risk score was subsequently derived. Conclusions: In NDLVC, male sex, non-sustained VT, LVEF < 45%, septal and ring-like LGE, high-risk genotypes, and myocardial inflammation predicted the first episode of MAE by 60 months.
- 18 July 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (1) , 94-106
Top Cited PapersMajor arrhythmias in non-dilated left ventricular cardiomyopathy: a novel prediction score
Background and Aims: The prediction of the first major arrhythmic event (MAE) is still an unmet need in the recently defined scenario of non-dilated left ventricular cardiomyopathy (NDLVC). Methods: A cohort of 337 patients with NDLVC and no history of MAE was retrospectively identified at two large centres. Patient-tailored diagnostic workup included cardiac magnetic resonance (CMR), endomyocardial biopsy, and genetic testing. The primary endpoint was the occurrence of the first MAE, including sustained ventricular tachycardia (VT), ventricular fibrillation, or appropriate implantable cardioverter-defibrillator therapy, by 60-month follow-up. A pool of 216 NDLVC patients from 11 European centres served as a validation cohort. Results: In the study cohort (mean age 37 ± 15 years, 62% male), the mean left ventricular ejection fraction (LVEF) was 52 ± 8%, and 79% of patients had late gadolinium enhancement (LGE) at baseline CMR. By 60-month follow-up, 51 patients (15%) experienced a MAE. The primary endpoint was predicted by male sex [hazard ratio (HR) 2.4, 95% confidence interval (CI) 1.3–4.4, P = .007], baseline non-sustained VT (HR 3.1, 95% CI 1.7–5.6, P < .001), LVEF < 45% (HR 5.5, 95% CI 2.7–11.0, P < .001), septal (HR 2.0, 95% CI 1.0–4.0, P = .046) and ring-like pattern of LGE (HR 1.3, 95% CI .6–2.6, P = .54), pathogenic/likely pathogenic variants in guideline-defined high-risk genes (HR 4.6, 95% CI 2.3–9.1, P < .001), and biopsy/CMR-proven myocardial inflammation (HR 15.7, 95% CI 6.1–40.3, P < .001). The results were confirmed in the validation cohort (Uno’s C-index 0.81, 95% CI .75–.88). A novel risk score was subsequently derived. Conclusions: In NDLVC, male sex, non-sustained VT, LVEF < 45%, septal and ring-like LGE, high-risk genotypes, and myocardial inflammation predicted the first episode of MAE by 60 months.
- Open Access
- 13 September 2024
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 26 (10)
Ventricular arrhythmias in acute heart failure: a clinical consensus statement of the Association for Acute CardioVascular Care, the European Heart Rhythm Association, and the Heart Failure Association of the European Society of Cardiology
Patients presenting with or alerting emergency networks due to acute heart failure (AHF) form a diverse group with a plethora of symptoms, risks, comorbidities, and aetiologies. During AHF, there is an increased risk of destabilizing the functional substrate and modulatory adding to the risk of ventricular arrhythmias (VAs) already created by the structural substrate. New VAs during AHF have previously identified patients with higher intra-hospital and 60-day morbidity and mortality. Risk stratification and criteria/best time point for coronary intervention and implantable cardioverter defibrillator implantation, however, are still controversial topics in this difficult clinical setting. The characteristics and logistics of pre-hospital emergency medicine, as well as the density of centres capable of treating AHF and VAs, differ massively throughout Europe. Scientific guidelines provide clear recommendations for the management of arrhythmias in patients with chronic heart failure. However, the incidence, significance, and management of arrhythmias in patients with AHF have been less studied. This consensus paper aimed to address the identification and treatment of VAs that complicate the course of patients who have AHF, including cardiogenic shock.
- 13 September 2024
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 26 (10)
Open AccessVentricular arrhythmias in acute heart failure: a clinical consensus statement of the Association for Acute CardioVascular Care, the European Heart Rhythm Association, and the Heart Failure Association of the European Society of Cardiology
Patients presenting with or alerting emergency networks due to acute heart failure (AHF) form a diverse group with a plethora of symptoms, risks, comorbidities, and aetiologies. During AHF, there is an increased risk of destabilizing the functional substrate and modulatory adding to the risk of ventricular arrhythmias (VAs) already created by the structural substrate. New VAs during AHF have previously identified patients with higher intra-hospital and 60-day morbidity and mortality. Risk stratification and criteria/best time point for coronary intervention and implantable cardioverter defibrillator implantation, however, are still controversial topics in this difficult clinical setting. The characteristics and logistics of pre-hospital emergency medicine, as well as the density of centres capable of treating AHF and VAs, differ massively throughout Europe. Scientific guidelines provide clear recommendations for the management of arrhythmias in patients with chronic heart failure. However, the incidence, significance, and management of arrhythmias in patients with AHF have been less studied. This consensus paper aimed to address the identification and treatment of VAs that complicate the course of patients who have AHF, including cardiogenic shock.
- 1 February 2024
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 30 (7) , 485-488
Anticoagulation in Patients with Atrial High-rate Episodes Detected by Cardiac Implantable Electronic Devices
Atrial high-rate episodes (AHRE) are atrial tachyarrhythmias that are identified by the use of continuous rhythm monitoring devices such as pacemakers, defibrillators, or implantable cardiac monitors. Nevertheless, the therapeutic implications of these rhythm disturbances remain uncertain. The presence of AHRE is associated with an increased risk of stroke as compared to patients who do not exhibit AHRE. The utilisation of oral anticoagulation has the ability to mitigate the likelihood of stroke occurrence in patients with AHRE. However, it is important to note that this treatment approach is also linked to a severe bleeding rate of approximately 2% per year. The stroke rate among individuals diagnosed with AHRE appears to be comparatively lower when compared to patients diagnosed with atrial fibrillation. The efficacy and safety of anticoagulation in patients with AHRE have yet to be definitively established. Further research is required to provide a comprehensive understanding of the effectiveness and safety of oral anticoagulation in individuals with AHRE.
- 1 February 2024
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 30 (7) , 485-488
Anticoagulation in Patients with Atrial High-rate Episodes Detected by Cardiac Implantable Electronic Devices
Atrial high-rate episodes (AHRE) are atrial tachyarrhythmias that are identified by the use of continuous rhythm monitoring devices such as pacemakers, defibrillators, or implantable cardiac monitors. Nevertheless, the therapeutic implications of these rhythm disturbances remain uncertain. The presence of AHRE is associated with an increased risk of stroke as compared to patients who do not exhibit AHRE. The utilisation of oral anticoagulation has the ability to mitigate the likelihood of stroke occurrence in patients with AHRE. However, it is important to note that this treatment approach is also linked to a severe bleeding rate of approximately 2% per year. The stroke rate among individuals diagnosed with AHRE appears to be comparatively lower when compared to patients diagnosed with atrial fibrillation. The efficacy and safety of anticoagulation in patients with AHRE have yet to be definitively established. Further research is required to provide a comprehensive understanding of the effectiveness and safety of oral anticoagulation in individuals with AHRE.
- Open Access
- 10 January 2024
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 10, 1351604
Editorial: Rising stars in cardiac rhythmology: 2023
Editorial: Rising stars in cardiac rhythmology: 2023
- 10 January 2024
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 10, 1351604
Open AccessEditorial: Rising stars in cardiac rhythmology: 2023
Editorial: Rising stars in cardiac rhythmology: 2023
- Open Access
- 26 December 2023
- Published by Baishideng Publishing Group Inc. in World Journal of Cardiology
- Vol. 15 (12) , 623-626
Inherited arrhythmias and gene therapy: Are there any ethical considerations to take into account?
Interventional electrophysiology represents a relatively recent subspecialty within the field of cardiology. In the past half-century, there has been significant advancement in the development and implementation of innovative ablation treatments and approaches. However, the treatment of arrhythmias continues to be inadequate. Several arrhythmias, such as ventricular tachycardia and atrial fibrillation, pose significant challenges in terms of therapeutic efficacy, whether through interventional procedures or the administration of antiarrhythmic drugs. Cardiologists are engaged in ongoing research to explore innovative methodologies, such as genome editing, with the purpose of effectively managing arrhythmias and meeting the growing needs of patients afflicted with rhythm disturbances. The field of genome editing has significant promise and has the potential to serve as a highly effective personalized therapy for rhythm disorders in patients. However, several ethical issues must be considered.
- 26 December 2023
- Published by Baishideng Publishing Group Inc. in World Journal of Cardiology
- Vol. 15 (12) , 623-626
Open AccessInherited arrhythmias and gene therapy: Are there any ethical considerations to take into account?
Interventional electrophysiology represents a relatively recent subspecialty within the field of cardiology. In the past half-century, there has been significant advancement in the development and implementation of innovative ablation treatments and approaches. However, the treatment of arrhythmias continues to be inadequate. Several arrhythmias, such as ventricular tachycardia and atrial fibrillation, pose significant challenges in terms of therapeutic efficacy, whether through interventional procedures or the administration of antiarrhythmic drugs. Cardiologists are engaged in ongoing research to explore innovative methodologies, such as genome editing, with the purpose of effectively managing arrhythmias and meeting the growing needs of patients afflicted with rhythm disturbances. The field of genome editing has significant promise and has the potential to serve as a highly effective personalized therapy for rhythm disorders in patients. However, several ethical issues must be considered.
- Open Access
- 20 November 2023
- Published by Elsevier in Hellenic Journal of Cardiology
- Vol. 78, 90-92
Current landscape in cardiology training, unmet needs, and attitudes on career development among cardiology trainees and young cardiologists in Greece: An HCS young cardiologists WG survey
- 20 November 2023
- Published by Elsevier in Hellenic Journal of Cardiology
- Vol. 78, 90-92
Open AccessCurrent landscape in cardiology training, unmet needs, and attitudes on career development among cardiology trainees and young cardiologists in Greece: An HCS young cardiologists WG survey
- Open Access
- 17 October 2023
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 10 (10) , 428
Progress in Cardiac Resynchronisation Therapy and Optimisation
Cardiac resynchronisation therapy (CRT) has become the cornerstone of heart failure (HF) treatment. Despite the obvious benefit from this therapy, an estimated 30% of CRT patients do not respond (“non-responders”). The cause of “non-response” is multi-factorial and includes suboptimal device settings. To optimise CRT settings, echocardiography has been considered the gold standard but has limitations: it is user dependent and consumes time and resources. CRT proprietary algorithms have been developed to perform device optimisation efficiently and with limited resources. In this review, we discuss CRT optimisation including the various adopted proprietary algorithms and conduction system pacing.
- 17 October 2023
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 10 (10) , 428
Open AccessProgress in Cardiac Resynchronisation Therapy and Optimisation
Cardiac resynchronisation therapy (CRT) has become the cornerstone of heart failure (HF) treatment. Despite the obvious benefit from this therapy, an estimated 30% of CRT patients do not respond (“non-responders”). The cause of “non-response” is multi-factorial and includes suboptimal device settings. To optimise CRT settings, echocardiography has been considered the gold standard but has limitations: it is user dependent and consumes time and resources. CRT proprietary algorithms have been developed to perform device optimisation efficiently and with limited resources. In this review, we discuss CRT optimisation including the various adopted proprietary algorithms and conduction system pacing.
- Open Access
- 27 April 2023
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 10
Hemodynamic support during catheter ablation of ventricular arrhythmias in patients with cardiogenic shock
Hemodynamic support during catheter ablation of ventricular arrhythmias in patients with cardiogenic shock
- 27 April 2023
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 10
Open AccessHemodynamic support during catheter ablation of ventricular arrhythmias in patients with cardiogenic shock
Hemodynamic support during catheter ablation of ventricular arrhythmias in patients with cardiogenic shock
- Open Access
- 23 March 2023
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 23 (1) , 1-3
Immunity and inflammation in cardiovascular disorders
Recent studies have developed our understanding of the role of the immune system and inflammation in Cardiovascular Disease (CVD), opening new avenues for risk stratification and therapeutic intervention. However, gaps in our knowledge remain. To address this issue, BMC Cardiovascular Disorders has launched a Collection on “Immunity and Inflammation in Cardiovascular Disorders”.
- 23 March 2023
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 23 (1) , 1-3
Open AccessImmunity and inflammation in cardiovascular disorders
Recent studies have developed our understanding of the role of the immune system and inflammation in Cardiovascular Disease (CVD), opening new avenues for risk stratification and therapeutic intervention. However, gaps in our knowledge remain. To address this issue, BMC Cardiovascular Disorders has launched a Collection on “Immunity and Inflammation in Cardiovascular Disorders”.